A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
Phase 3
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung
Both
Carcinoma, Non-Small-Cell Lung
Trial Information
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
Inclusion Criteria:
1. Stage IIIB or IV non-small lung cancer
2. Able to visit the doctor's office
3. At least 18 years of age
4. Adequate kidney, adrenal, and liver function
Exclusion Criteria:
1. Prior chemotherapy or biologic therapy for NSCLC
2. Central nervous system tumors
3. Pregnant or breastfeeding
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
6428
NCT ID:
NCT00034268
Start Date:
March 2002
Completion Date:
Related Keywords:
- Carcinoma, Non-Small-Cell Lung
- non-small cell lung cancer
- Stage IIIB or IV non-small cell lung cancer (NSCLC)
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Alexandria, Minnesota 56308 | |
| Albany, Georgia 31701 | |
| Fountain Valley, California 92708 | |
| Albany, New York 12208 | |
| Austin, Texas 78705 | |
| Flint, Michigan 48532 | |
| McLean, Virginia 22101 | |
| Little Rock, Arkansas 72205-7199 | |
| Metairie, Louisiana 70006 | |
| Denver, Colorado | |
| Baltimore, Maryland 21287 | |
| Milwaukee, Wisconsin | |
| Wilmington, Delaware | |
| Indianapolis, Indiana |
